Sponsored Content by EvotecReviewed by Ify IsiborAug 19 2026
Given that current therapeutics primarily target proteins, proteomic technologies are transforming the analytical toolkit available to facilitate pre-clinical pharmaceutical discovery.
Image Credit:Shutterstock.com/dhean kate
Recent advancements in workflows and instrumentation have enabled the successful application of mass spectrometry (MS)-based quantitative proteomics for holistic proteome-scale profiling, supporting the discovery of therapeutics that target proteins previously considered undruggable.
As a result, the pharmaceutical and biotech sectors have shown increasing interest in molecular glues, targeted protein degraders (TPD), targeted protein stabilizers (TPS), and targeted covalent ligands.
ScreenPep – proteomics without compromise
Evotec operates one of the world’s largest high-end mass spectrometry sites for next-generation proteomics research. With over two decades of expertise in mass spectrometry, chemical proteomics, and cutting-edge data analytics, Evotec provides a wide variety of state-of-the-art mass-spectrometry-based proteomic technologies and services to tackle key challenges in pharmaceutical and biomarker discovery.
Evotec continuously advances its mass-spectrometry-based proteomics capabilities to ensure unmatched understanding and high-quality data during the analysis of cells, animal models, and patient samples.
The recent introduction of Evotec’s ScreenPep2.0 platform further fuels the paradigm shift toward unmatched higher-throughput proteomics profiling without compromising on precision or coverage.
Evotec employs the latest versions of automated and multiplexed sample preparation, combined with rapid and parallelized sample processing across the latest high-end liquid chromatography coupled to tandem mass spectrometry (LCMS/MS) technology.
These capabilities allow the company to achieve the throughput required for large-scale discovery proteomics projects, supporting as many as several thousand samples each day.
ScreenPep is a single-shot data-independent acquisition (DIA)-based protein quantification workflow that provides ultra-deep proteome coverage while enabling repeatable and accurate quantification of more than 10,000 proteins per sample.1
By offering a scalable, tractable, and completely automated proteome-based pipeline in human cell lines, ScreenPep facilitates the screening of small molecules that bind to or alter the abundance of endogenous proteins, including targeted protein degraders and stabilizers.
Figure 1. Overview of the ScreenPep platform. Image Credit: Evotec
Acknowledgments
Produced from materials originally authored by Francois Autelitano, VP Translational Proteomics and Metabolomics.
References and further reading
- Gillet, L.C., et al. (2012). Targeted Data Extraction of the MS/MS Spectra Generated by Data-independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis. Molecular & Cellular Proteomics, 11(6), p.O111.016717. DOI:10.1074/mcp.o111.016717. https://www.mcponline.org/article/S1535-9476(20)30442-4/fulltext.
About Evotec
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure – faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Evotec’s global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us LinkedIn and X/Twitter @Evotec
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.